Ó³»­´«Ã½

Benjamin Ebert is an associate member of the Ó³»­´«Ã½ of MIT and Harvard, where he serves on the board of directors. He is also president and chief executive officer at the Dana-Farber Cancer Institute and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. He is also the director of the Dana-Farber/Harvard Cancer Center.

focuses on the molecular basis and treatment of hematologic malignancies and their non-malignant precursor conditions, with a particular focus on myelodysplastic syndromes (MDS) and clonal hematopoiesis. The Ebert laboratory demonstrated that lenalidomide, a derivative of thalidomide, binds the CRL4-CRBN E3 ubiquitin ligase and induces degradation of specific substrates. Subsequent research has examined novel mechanisms of drug-induced protein degradation that expand the spectrum of protein substrates that can be targeted pharmacologically.

Ebert is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation, the Association of American Physicians, and the Academy of the American Association for Cancer Research. He served as president of the American Society for Clinical Investigation in 2017 and currently serves on the board of directors for Break Through Cancer.

Ebert received the William Dameshek Prize from the American Society of Hematology, the Meyenburg Prize for Cancer Research, the Sjöberg Prize from the Royal Swedish Academy of Sciences, and the Korsmeyer Award from the American Society for Clinical Investigation. He has received awards from Harvard Medical School and the Harvard-MIT Health Sciences and Technology Program for mentorship.

Ebert received a bachelor's degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute before pursuing postdoctoral research at the Ó³»­´«Ã½.